Hikma Pharmaceuticals (BATS-CHIXE:HIKL) - Stock Price, News & Analysis

HIKL Stock Overview

Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. More details

HIKL fundamental analysis
Snowflake Score
Valuation	6/6
Future Growth	2/6
Past Performance	3/6
Financial Health	4/6
Dividends	5/6

Rewards

Trading at 50.4% below our estimate of its fair value

Earnings are forecast to grow 12.84% per year

Earnings grew by 95.2% over the past year

Pays a reliable dividend of 3.35%

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 24.4%

Risk Analysis

Has a high level of debt

Large one-off items impacting financial results

Hikma Pharmaceuticals PLC Competitors

GSK

LSE:GSK

UK£54.8b

Animalcare Group

AIM:ANCR

UK£148.5m

AstraZeneca

LSE:AZN

UK£162.4b

ECO Animal Health Group

AIM:EAH

UK£44.7m

Price History & Performance

Summary of all time highs, changes and price drops for Hikma Pharmaceuticals
Historical stock prices
Current Share Price	UK£18.66
52 Week High	UK£21.61
52 Week Low	UK£17.11
Beta	0.44
11 Month Change	-6.79%
3 Month Change	-6.84%
1 Year Change	6.23%
33 Year Change	-19.22%
5 Year Change	-3.52%
Change since IPO	192.25%

Recent updates

Shareholder Returns

	HIKL	GB Pharmaceuticals	GB Market
7D	3.9%	-2.3%	0.8%
1Y	6.2%	-2.7%	6.6%

Return vs Industry: HIKL exceeded the UK Pharmaceuticals industry which returned -2.8% over the past year.

Return vs Market: HIKL matched the UK Market which returned 6.1% over the past year.

Price Volatility

Is HIKL's price volatile compared to industry and market?
HIKL volatility
HIKL Average Weekly Movement	2.7%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: HIKL has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: HIKL's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1978	9,100	Riad Mishlawi	www.hikma.com

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.

Hikma Pharmaceuticals PLC Fundamentals Summary

How do Hikma Pharmaceuticals's earnings and revenue compare to its market cap?
HIKL fundamental statistics
Market cap	UK£4.15b
Earnings (TTM)	UK£226.27m
Revenue (TTM)	UK£2.40b

18.3x

P/E Ratio

1.7x

P/S Ratio

Is HIKL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HIKL income statement (TTM)
Revenue	US$3.02b
Cost of Revenue	US$1.57b
Gross Profit	US$1.45b
Other Expenses	US$1.16b
Earnings	US$285.00m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.29
Gross Margin	47.99%
Net Profit Margin	9.45%
Debt/Equity Ratio	53.2%

How did HIKL perform over the long term?

See historical performance and comparison

Dividends

3.4%

Current Dividend Yield

61%

Payout Ratio

HIKL Stock Overview

Rewards

Risk Analysis

Hikma Pharmaceuticals PLC Competitors

LSE:GSK

UK£54.8b

AIM:ANCR

UK£148.5m

LSE:AZN

UK£162.4b

AIM:EAH

UK£44.7m

Price History & Performance

Recent News & Updates

Hikma Pharmaceuticals plc Announces the Shelf-Life Extension of KLOXXADO Nasal Spray 8mg from 24 to 36 Months

Hikma Pharmaceuticals PLC Revises Group Earnings Guidance for the Full Year of 2024

Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024

Hikma Pharmaceuticals PLC Announces Executive Changes

Upcoming dividend of US$0.47 per share

Now 21% undervalued

Recent updates

Hikma Pharmaceuticals plc Announces the Shelf-Life Extension of KLOXXADO Nasal Spray 8mg from 24 to 36 Months

Hikma Pharmaceuticals PLC Revises Group Earnings Guidance for the Full Year of 2024

Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024

Hikma Pharmaceuticals PLC Announces Executive Changes

Upcoming dividend of US$0.47 per share

Now 21% undervalued

Final dividend of US$0.47 announced

Full year 2023 earnings released: EPS: US$0.86 (vs US$0.84 in FY 2022)

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 25, 2024

Hikma Announces US Launch of COMBOGESIC IV

Now 22% undervalued after recent price drop

Hikma Pharmaceuticals PLC Announces Company Secretary Change

Hikma Pharmaceuticals PLC to Report First Half, 2024 Results on Aug 08, 2024

Hikma Pharmaceuticals PLC Provides Earnings Guidance for the Year 2023

Hikma Pharmaceuticals PLC(LSE:HIK) dropped from FTSE 250 Index

Now 21% undervalued

New minor risk - Insider selling

Insider recently sold UK£543k worth of stock

Hikma Pharmaceuticals PLC Appoints Bill Larkins as President of Its Injectables Business, Effective 1 September 2023

First half 2023 earnings released: EPS: US$0.59 (vs US$0.76 in 1H 2022)

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Hikma Exceeds 150 Injectable Medicines in the US with Launch of Dobutamine Injection, USP

Now 21% undervalued

Upcoming dividend of US$0.37 per share at 2.7% yield

Full year 2022 earnings released: EPS: US$0.84 (vs US$1.82 in FY 2021)

Hikma Launches Authorized Generic of Xyrem® (Sodium Oxybate) in the US

Hikma Pharmaceuticals PLC to Report Fiscal Year 2022 Results on Feb 23, 2023

Hikma Pharmaceuticals PLC Appoints Deneen Vojta as Director

Hikma Pharmaceuticals PLC Announces Board Appointments

Investor sentiment improved over the past week

Hikma Pharmaceuticals PLC(LSE:HIK) dropped from FTSE 100 Index

Hikma Pharmaceuticals PLC and Glenmark Specialty S.A., Launches RYALTRIS in US

Upcoming dividend of US$0.19 per share

First half 2022 earnings released

Hikma Pharmaceuticals plc Recommends Interim Dividend, Payable on 19 September 2022

Insufficient new directors

Insufficient new directors

Hikma Pharmaceuticals plc Announces Company Secretary Change

Hikma Pharmaceuticals PLC Announces Chief Executive Officer Changes

Hikma Pharmaceuticals PLC Approves Final Dividend for the Year 2021

Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Custopharm Inc. from Water Street Healthcare Partners, LLC.

Upcoming dividend of US$0.36 per share

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Hikma Pharmaceuticals PLC (LSE:HIK) announces an Equity Buyback for £300 million worth of its shares.

Hikma Pharmaceuticals PLC Provides Revenue Guidance for 2022

Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).

Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million.

Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Custopharm Inc. from Water Street Healthcare Partners, LLC for approximately $430 million.

Upcoming dividend of US$0.18 per share

First half 2021 earnings released: EPS US$1.07 (vs US$0.88 in 1H 2020)

Hikma Pharmaceuticals PLC Announces US FDA Approval of KLOXXADO

New 90-day low: UK£22.38

Full year 2020 earnings released: EPS US$1.83 (vs US$2.01 in FY 2019)

Revenue beats expectations

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 23, 2021

Eyevance Pharmaceuticals Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma

Hikma Pharmaceuticals PLC to Report Fiscal Year 2020 Results on Feb 25, 2021

Hikma Pharmaceuticals PLC (LSE:HIK) entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E (CASE:BIOC) from Glaxo Group Limited.